Elotuzumab is under clinical development by AbbVie and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs for Myelofibrosis have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elotuzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elotuzumab (HuLuc63/Empliciti) is a humanized anti-CS1 monoclonal IgG1 antibody acts as an antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (Relapsed/Refractory) who have received one to three prior therapies, and also in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (Relapsed/Refractory) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor and in combination with pomalidomide and dexamethasone is indicated for the treatment of patients with relapsed and refractory multiple myeloma.
The drug candidate is under development for the treatment of IgG4 related disease, multiple myeloma (first line), post-essential thrombocythemia myelofibrosis (Post-ET MF) and primary myelofibrosis.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of Elotuzumab’s drug-specific PTSR and LoA scores, buy the report here.